Compare RNAZ & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNAZ | ELAB |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.7M |
| IPO Year | 2021 | N/A |
| Metric | RNAZ | ELAB |
|---|---|---|
| Price | $4.90 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.4K | ★ 835.5K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.82 | $0.66 |
| 52 Week High | $20.99 | $15.00 |
| Indicator | RNAZ | ELAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 31.93 |
| Support Level | $3.82 | $0.66 |
| Resistance Level | $6.15 | $1.97 |
| Average True Range (ATR) | 0.67 | 0.11 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 50.77 | 3.54 |
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.